Automatic analysis of skull thickness, scalp-to-cortex distance and association with age and sex in cognitively normal elderly

Alzheimer's Disease Neuroimaging Initiative

doi:10.1016/j.brs.2023.03.011

Automatic analysis of skull thickness, scalp-to-cortex distance and association with age and sex in cognitively normal elderly

Alzheimer's Disease Neuroimaging Initiative

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English
Pages (from-to)	653-656
Number of pages	4
Journal	Brain Stimulation
Volume	16
Issue number	2
DOIs	https://doi.org/10.1016/j.brs.2023.03.011
State	Published - 1 Mar 2023
Externally published	Yes

Keywords

ADNI
Ageing
MRI
Scalp-to-cortex distance
Skull thickness

Access to Document

10.1016/j.brs.2023.03.011

Cite this

@article{45154319caa54990b883722e2df34955,

title = "Automatic analysis of skull thickness, scalp-to-cortex distance and association with age and sex in cognitively normal elderly",

keywords = "ADNI, Ageing, MRI, Scalp-to-cortex distance, Skull thickness",

author = "{Alzheimer's Disease Neuroimaging Initiative} and Junhao Zhang and Valerie Treyer and Junfeng Sun and Chencheng Zhang and Anton Gietl and Christoph Hock and Daniel Razansky and Nitsch, {Roger M.} and Ruiqing Ni",

note = "Funding Information: Data collection and sharing for this project was funded by the ADNI (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Funding Information: RN received funding from Helmut Horten Stiftung , and Vontobel Stiftung . ",

year = "2023",

month = mar,

day = "1",

doi = "10.1016/j.brs.2023.03.011",

language = "English",

volume = "16",

pages = "653--656",

journal = "Brain Stimulation",

issn = "1935-861X",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Automatic analysis of skull thickness, scalp-to-cortex distance and association with age and sex in cognitively normal elderly

AU - Alzheimer's Disease Neuroimaging Initiative

AU - Zhang, Junhao

AU - Treyer, Valerie

AU - Sun, Junfeng

AU - Zhang, Chencheng

AU - Gietl, Anton

AU - Hock, Christoph

AU - Razansky, Daniel

AU - Nitsch, Roger M.

AU - Ni, Ruiqing

N1 - Funding Information: Data collection and sharing for this project was funded by the ADNI (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Funding Information: RN received funding from Helmut Horten Stiftung , and Vontobel Stiftung .

PY - 2023/3/1

Y1 - 2023/3/1

KW - ADNI

KW - Ageing

KW - MRI

KW - Scalp-to-cortex distance

KW - Skull thickness

UR - http://www.scopus.com/inward/record.url?scp=85150770190&partnerID=8YFLogxK

U2 - 10.1016/j.brs.2023.03.011

DO - 10.1016/j.brs.2023.03.011

M3 - Letter

AN - SCOPUS:85150770190

SN - 1935-861X

VL - 16

SP - 653

EP - 656

JO - Brain Stimulation

JF - Brain Stimulation

IS - 2

ER -

Automatic analysis of skull thickness, scalp-to-cortex distance and association with age and sex in cognitively normal elderly

Keywords

Access to Document

Other files and links

Cite this